IL253796A0 - Therapeutically active compounds and methods of use - Google Patents
Therapeutically active compounds and methods of useInfo
- Publication number
- IL253796A0 IL253796A0 IL253796A IL25379617A IL253796A0 IL 253796 A0 IL253796 A0 IL 253796A0 IL 253796 A IL253796 A IL 253796A IL 25379617 A IL25379617 A IL 25379617A IL 253796 A0 IL253796 A0 IL 253796A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- active compounds
- therapeutically active
- therapeutically
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
- G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
- G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
- G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112127P | 2015-02-04 | 2015-02-04 | |
| PCT/US2016/016335 WO2016126798A1 (en) | 2015-02-04 | 2016-02-03 | Therapeutically active compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL253796A0 true IL253796A0 (en) | 2017-09-28 |
Family
ID=55640843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253796A IL253796A0 (en) | 2015-02-04 | 2017-08-02 | Therapeutically active compounds and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10201543B2 (enExample) |
| EP (1) | EP3253746A1 (enExample) |
| JP (3) | JP7220986B6 (enExample) |
| KR (1) | KR102628370B1 (enExample) |
| CN (1) | CN107531675A (enExample) |
| CA (1) | CA2975506A1 (enExample) |
| IL (1) | IL253796A0 (enExample) |
| WO (1) | WO2016126798A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017821A2 (en) | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| CA3001599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MX381582B (es) | 2015-10-15 | 2025-03-12 | Celgene Corp | Terapia de combinacion para el tratamiento de neoplasias malignas. |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017146795A1 (en) | 2016-02-26 | 2017-08-31 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| US20220017489A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US20220017490A1 (en) * | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
| LT2800743T (lt) | 2012-01-06 | 2018-06-25 | Agios Pharmaceuticals, Inc. | Terapiškai aktyvūs junginiai ir jų panaudojimo būdai |
| ES2807582T3 (es) | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer |
| WO2015017821A2 (en) | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015018060A1 (en) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| CA3001599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017146795A1 (en) | 2016-02-26 | 2017-08-31 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
-
2016
- 2016-02-03 WO PCT/US2016/016335 patent/WO2016126798A1/en not_active Ceased
- 2016-02-03 CN CN201680020656.7A patent/CN107531675A/zh active Pending
- 2016-02-03 US US15/548,737 patent/US10201543B2/en active Active
- 2016-02-03 JP JP2017541075A patent/JP7220986B6/ja active Active
- 2016-02-03 CA CA2975506A patent/CA2975506A1/en not_active Abandoned
- 2016-02-03 EP EP16712552.5A patent/EP3253746A1/en not_active Withdrawn
- 2016-02-03 KR KR1020177024658A patent/KR102628370B1/ko active Active
-
2017
- 2017-08-02 IL IL253796A patent/IL253796A0/en unknown
-
2018
- 2018-12-21 US US16/230,090 patent/US10434105B2/en active Active
-
2020
- 2020-10-28 JP JP2020180152A patent/JP2021038227A/ja active Pending
-
2022
- 2022-11-01 JP JP2022175208A patent/JP2023011792A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016126798A1 (en) | 2016-08-11 |
| JP2021038227A (ja) | 2021-03-11 |
| EP3253746A1 (en) | 2017-12-13 |
| JP7220986B6 (ja) | 2024-02-08 |
| KR20170113628A (ko) | 2017-10-12 |
| US20190117662A1 (en) | 2019-04-25 |
| CA2975506A1 (en) | 2016-08-11 |
| US10201543B2 (en) | 2019-02-12 |
| US10434105B2 (en) | 2019-10-08 |
| CN107531675A (zh) | 2018-01-02 |
| US20180028539A1 (en) | 2018-02-01 |
| KR102628370B1 (ko) | 2024-01-24 |
| JP2023011792A (ja) | 2023-01-24 |
| JP7220986B2 (ja) | 2023-02-13 |
| JP2018504429A (ja) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL270347B (en) | Therapeutically active compounds and methods of use | |
| IL251246A0 (en) | Therapeutically active compounds and methods of use | |
| ZA201600667B (en) | Therapeutically active compounds and their methods of use | |
| HUE068842T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| SG11201802794PA (en) | Therapeutic compounds and methods | |
| EP3377070A4 (en) | COMPOUNDS AND METHOD FOR THEIR USE | |
| PT3258951T (pt) | Anticorpos anti-pvrig e métodos de utilização | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| GB201514760D0 (en) | Compounds and method of use | |
| IL265955A (en) | Therapeutic compounds and methods of using them | |
| IL255565A (en) | Substituted benzamides and methods of use thereof | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| IL285882A (en) | Medicinal uses for l–4–chlorokynurenine | |
| IL254783B (en) | Combinations for deworming methods for using them | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| PT3397364T (pt) | Elementos estruturados e métodos de utilização | |
| ZA201802134B (en) | Therapeutic compounds and methods of use thereof | |
| ZA201700571B (en) | Therapeutically active compounds and their methods of use | |
| EP3212202A4 (en) | Use of therapeutic agents | |
| AU2014904330A0 (en) | Use of therapeutic agents |